AstraZeneca buys Novexel for up to $505 million in antibiotic gambit
24 December 2009
Christopher Spillane
AstraZeneca has agreed to acquire
Novexel in an all-cash deal worth up to $505 million that deepens the UK pharma firm's antibiotic portfolio.
AstraZeneca will buy Novexel, which was spun out of Aventis Pharma in late 2004, for $350 million cash and will pay up to $75 million in development...
Please Login to read the full article.
24 December 2009
Christopher Spillane
AstraZeneca will buy Novexel, which was spun out of Aventis Pharma in late 2004, for $350 million cash and will pay up to $75 million in development...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Stockwatch: The difficult art of painting oneself out of a corner
- Cempra dives into tough IPO pool, filing $86M IPO for Phase II antibiotics
- Bayer licenses non-US/EU rights to Trius' torezolid for $25M up front
- US bill aims to provide exclusivity, other incentives for antibiotic makers
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
